Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC–MS/MS: Its pharmacokinetic application

•The method is novel, selective, sensitive, rugged, efficient and cost effective.•Low plasma volume assay 0.2mL allows additional time points for sample collection.•Method involved a simple, quick, clean and specific sample preparation by SPE.•Short run time 2.0min under isocratic conditions ensures...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of pharmaceutical and biomedical analysis Vol. 90; pp. 64 - 71
Main Authors:	Bonde, S.L., Bhadane, R.P., Gaikwad, Avinash, Gavali, S.R., Katale, D.U., Narendiran, A.S.
Format:	Journal Article
Language:	English
Published:	England Elsevier B.V 01-03-2014
Subjects:	Adult Benzodiazepines - administration & dosage Benzodiazepines - pharmacokinetics Bioequivalence Calibration Chromatography, Liquid - methods Cross-Over Studies Drug Combinations Fluoxetine Fluoxetine - administration & dosage Fluoxetine - pharmacokinetics Human plasma Humans LC–MS/MS Male Olanzapine Reproducibility of Results Sensitivity and Specificity Serotonin Uptake Inhibitors - administration & dosage Serotonin Uptake Inhibitors - pharmacokinetics Solid Phase Extraction - methods Tandem Mass Spectrometry - methods Therapeutic Equivalency Olanzapine Human plasma Bioequivalence Fluoxetine LC–MS/MS
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•The method is novel, selective, sensitive, rugged, efficient and cost effective.•Low plasma volume assay 0.2mL allows additional time points for sample collection.•Method involved a simple, quick, clean and specific sample preparation by SPE.•Short run time 2.0min under isocratic conditions ensures much higher throughput.•LLOQ is sufficiently low 0.1ng/mL and suits perfectly for a BE study. A simple and rapid liquid chromatography/tandem mass spectrometry (LC–MS/MS) method has been developed and validated for the simultaneous quantitation of Olanzapine and Fluoxetine in human plasma using Olanzapine-d3 and Fluoxetine-d5 HCl as internal standard (IS), respectively. After solid phase extraction of the plasma samples on Waters Oasis HLB Catridges, Olanzapine, Fluoxetine and IS were chromatographed on Thermo Hypersil Gold C18 (50mm×4.6mmi.d., 5μm) analytical column with isocratic elution using methanol: 2mM Ammonium acetate buffer (90:10). Quantitation was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique and operating in multiple reaction monitoring (MRM) and positive ion mode with transitions at 313/256 for Olanzapine and 310/148 for Fluoxetine. The total chromatographic run time was 2.0min and calibration curves were linear over the concentration range of 0.10–20.00ng/mL for Olanzapine and 0.50–50.00ng/mL for Fluoxetine. The method was validated for selectivity, sensitivity, recovery, linearity, accuracy and precision and stability studies. The recoveries obtained for the Olanzapine and its IS was ≥87% and Fluoxetine and its IS was ≥91%. Recoveries obtained were consistent and reproducible. Inter-batch and intra-batch coefficient of variation across three validation runs (LLOQ, LQC, MQC1, MQC and HQC) was less than 3.6 for Olanzapine and less than 5.2% for Fluoxetine. The method was successfully applied to a pharmacokinetic study of fixed dose combination of Olanzapine/Fluoxetine in healthy male volunteers.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23
ISSN:	0731-7085 1873-264X
DOI:	10.1016/j.jpba.2013.10.033